These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
243 related articles for article (PubMed ID: 26549591)
1. Personalising the treatment of prostate cancer. Gunjur A Lancet Oncol; 2015 Dec; 16(16):e592. PubMed ID: 26549591 [No Abstract] [Full Text] [Related]
2. Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial. Le Tourneau C; Delord JP; Gonçalves A; Gavoille C; Dubot C; Isambert N; Campone M; Trédan O; Massiani MA; Mauborgne C; Armanet S; Servant N; Bièche I; Bernard V; Gentien D; Jezequel P; Attignon V; Boyault S; Vincent-Salomon A; Servois V; Sablin MP; Kamal M; Paoletti X; Lancet Oncol; 2015 Oct; 16(13):1324-34. PubMed ID: 26342236 [TBL] [Abstract][Full Text] [Related]
3. Drug sensitivity testing platforms for gastric cancer diagnostics. Lau V; Wong AL; Ng C; Mok Y; Lakshmanan M; Yan B J Clin Pathol; 2016 Feb; 69(2):93-6. PubMed ID: 26567318 [TBL] [Abstract][Full Text] [Related]
5. Lack of access to targeted cancer therapy. Burki TK Lancet Oncol; 2015 Oct; 16(13):e482. PubMed ID: 26321211 [No Abstract] [Full Text] [Related]
6. A precision, personalized approach to the management of bladder cancer. Apolo AB; Burger M Curr Opin Urol; 2015 Sep; 25(5):416-7. PubMed ID: 26153639 [No Abstract] [Full Text] [Related]
7. Precision medicine beyond medical oncology: using molecular analysis to guide treatments of colorectal neoplasia. Molloy MP; Engel A Expert Rev Gastroenterol Hepatol; 2018 Dec; 12(12):1179-1181. PubMed ID: 30791786 [No Abstract] [Full Text] [Related]
8. Is Precision Medicine an Oxymoron? Eckhardt SG; Lieu C JAMA Oncol; 2019 Feb; 5(2):142-143. PubMed ID: 30419105 [No Abstract] [Full Text] [Related]
9. Maurie Markman on the Groundbreaking TAPUR Trial. Markman M Oncology (Williston Park); 2017 Mar; 31(3):158, 168. PubMed ID: 28299751 [No Abstract] [Full Text] [Related]
10. Detection of Chromosomal Abnormalities with Different In Situ Hybridisation Techniques--the Usefulness in the Qualification of Cancer Patients for Molecularly-Targeted Therapies. Nicoś M; Wojas-Krawczyk K; Krawczyk P; Milanowski J Adv Clin Exp Med; 2015; 24(4):715-23. PubMed ID: 26469118 [TBL] [Abstract][Full Text] [Related]
12. Anticipating designer drug-resistant cancer cells. Frangione ML; Lockhart JH; Morton DT; Pava LM; Blanck G Drug Discov Today; 2015 Jul; 20(7):790-3. PubMed ID: 25697478 [TBL] [Abstract][Full Text] [Related]
13. Next-Generation Sequencing in Oncology in the Era of Precision Medicine. Blumenthal GM; Mansfield E; Pazdur R JAMA Oncol; 2016 Jan; 2(1):13-4. PubMed ID: 26540172 [No Abstract] [Full Text] [Related]
14. New ESMO scale ranks mutations as cancer medicine targets. Fricker J Lancet Oncol; 2018 Oct; 19(10):e513. PubMed ID: 30177495 [No Abstract] [Full Text] [Related]
15. Unfavorable Pathology, Tissue Biomarkers and Genomic Tests With Clinical Implications in Prostate Cancer Management. Nguyen JK; Magi-Galluzzi C Adv Anat Pathol; 2018 Sep; 25(5):293-303. PubMed ID: 29727322 [TBL] [Abstract][Full Text] [Related]
16. Personalized Medicine: Genomics Trials in Oncology. Hayes DF; Schott AF Trans Am Clin Climatol Assoc; 2015; 126():133-43. PubMed ID: 26330667 [TBL] [Abstract][Full Text] [Related]
17. Using Somatic Mutations to Guide Treatment Decisions: Context Matters. Horlings HM; Shah SP; Huntsman DG JAMA Oncol; 2015 Jun; 1(3):275-6. PubMed ID: 26181166 [No Abstract] [Full Text] [Related]